The role of endothelial dysfunction driven by adipocitokines in the development and progression of microvascular complications in patients with type 1 and type 2 diabetes

Kristina Blaslov[1], MD; Tomislav Bulum[1], MD, PhD; Lea Duvnjak[1], MD, PhD, Professor

[1]Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, School of Medicine Zagreb, Croatia

Correspondence to: Kristina Blaslov, MD; Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur,

Dugi dol 4a, Zagreb, Croatia.

e-mail: kblaslov@gmail.com

Tel/Fax: 0038512353829

Funding/Grant: The authors did not receive any financial support for this work.

Abstract

Micro and macrovascular complications are the leading cause of morbidity and mortality in diabetic patients. During the last decades attention has been focused on their early diagnosis and prevention. Diabetes related metabolic abnormalities: insulin resistance, hyperglycaemia and dyslipidaemia along with oxidative stress and low- grade inflammation contribute to the development of endothelial dysfunction and macrovascular complications. Recent investigations indicate a potential role of adipocitokines originating from visceral adipose tissue: adiponectin, leptin, resistin and dipepetidyl peptidase- 4 (DPP-4) activity in the development of microvascular complications in diabetes. The association of these adipocitokines with the activity of endothelial synthetase (eNOS) involved into the metabolism of nitric oxide (NO) was documented in animal and cell culture studies. We hypothesize that lower adiponectin and higher leptin and resistin plasma concentration and DPP-4 activity are associated with the development and progression of diabetic microvascular complications by endothelial function impairment.

A possible identification of new markers of the complex pathophysiologydevelopment and progression of microvascular complications in diabeteswill contribute to improved diagnosis followed by an individualized patients approach.

Background

The estimated prevalence of diabetes mellitus (DM) is currently about 382 million, or 8.3% of the world population aged 20-79 years (1). Due to the high impact on morbidity and mortality the prevention and early diagnosis of diabetic vascular complications is in the focus of scientific and professional interest. Diabetic retinopathy is the leading cause of blindness (2), diabetic nephropathy is the most important cause of renal failure (3), and macrovascular complications are the leading cause of death in more than two-thirds of diabetic patients (4). Endothelial cell dysfunction (ECD) is pathophysiologically related to all vascular complications of diabetes (5). Reduced bioavailability of nitric oxide (NO) (6) indirectly contributes to metabolic disorders of diabetes: hyperglycaemia and dyslipidaemia along with oxidative stress and low grade inflammation in the microvascular complications development (7).

Visceral adipose tissue represents a hormonally active organ by secreting various adipocytokines implicated in the regulation of metabolic homeostasis (8). Studies demonstrating the effects of insulin resistance (IR) related adipocytokines: adiponectin, leptin, resistin and dipeptidyl peptidase-4 (DPP4) on endothelial NO sintetase (eNOS) have implicated their possible contribution to the development and progression of microvascular complications independently of traditional risk factors. However, their association with retinopathy, nephropathy and neuropathy through modulation of endothelial physiology has not been extensively studied.

The hypothesis

We hypothesisethat lower plasma concentrationof adiponectin, while higher concentrationof leptin, resistinandserum DPP4activity contribute to the development and progression of diabetic microvascular complications through endothelial function impairment.Insulin

resistance (IR) contributes directly to the development of ECD modulating the activity of eNOS (9) and impairing other metabolic processes in diabetes (10). Prospective clinical studies have shown that abnormalities associated with ECD were causally related with the development and progression of microvascular complications in DM (11-13). Stehouwer et al. (2012) in longitudinal study in 328 patients with type 2 diabetes (T2DM) has shown that the level of ECD was associated with progression of nephropathy both in relation to and independently of traditional risk factors (14). The results of cross-sectional studies in patients with type 1 diabetes (T1DM) have also indicated that ECD might be more strongly associated with the development of microvascular complications in comparison with traditional risk factors (15). For that reason it seems to be of special scientific and clinical interest to investigate for new ECD related risk factors associated with the development and progression of microvascular complications in diabetes.

Evaluation of the hypothesis

Leptin is the oldest known adipocytokine (16). A higher plasma concentration of leptin is associated with the development and progression of microvascular complications in patients with T2DM (17-19). At the molecular level the effectof leptinonendothelial functionis unclear as leptin both stimulates the activity ofeNOS andreducesthe bioavailability ofL-argininerequiredfor NO synthesis(20-22). In addition, the results of studies exploring the relationship between leptin and microvascularcomplications in patients with T1DM arecontroversial(23).

Adiponectin is the most extensively studied adipocytokine in the context of their association with microvascular complications in diabetes. In T2DM plasma concentration is inversely associated with retinopathy (25) and urinary albumin excretion rate (UAE), an early marker of renal microvasculature (26). However, in T1DM the relationof adiponectinwithretinopathy,

albuminuriaandnephropathyis not fully understood(20,29-31). Insome studies a positive correlationof adiponectinwithretinopathy andalbuminuria in T1DM was found (29, 30). In animal and cell culture studies adiponectin increased the bioavailability of NO directly, stimulating eNOS, and indirectly, by reducing the concentration of superoxide products (27-29). Sharma et al. (2008) have shown in an animal model of T1DM that the retraction of podocyte cells representing the primary changes in diabetic nephropathy correlated with the superoxide concentrations (32). To explain elevatedconcentrationsof adiponectininpatients with T1DM andmicrovascular complications the authorhypothesizedthat an increase inadiponectin level might represent aprotective mechanism aimed to suppress superoxide effects on eNOS(31, 33).

An elevated plasma concentration of resistin was also found in T1DM and T2DM. Its effect on IR is thought to be mediated through proinflammatory activity (34). The association of resistin with the prevalence of microvascular complications has not been extensively investigated. Azab et al. (2012) (35) have recently demonstrated in 30 patients with T2DM that resistin concentrations was associated with retinopathy. This is in support to the results of Osawa et al. (2007) who previously showed resistin relations with all microvascular complications in T2DM (37). However, other studies have not confirmed their results (36). It was not clarified whether resistin effect on inhibition of eNOS activity (37) and the development and progression of microvascular complications is independent of low-grade inflammation and IR (38).

The results of recent experimental studies suggest an increased expression of DPP-4 in adipocytes of visceral fat and increased serum enzymes in patients with IR and T2DM (39, 40). In vitro studies also suggest a possible link between DPP4 activity and renovascular protective effect (41, 42). However, the role of the serum DPP-4 enzyme in the pathogenesis of chronic microvascular complications in diabetes has not been systematically investigated.

Inhibition of DPP4 activity leads to increased eNOS activity, although it is not clear whether this represent a directeffect ofDPP4 activity (43-45).

Conclusion

We hypothesisethat lower plasma concentrationof adiponectin, while higher concentrationof leptin, resistinandserum DPP4activity contribute to the development and progression of diabetic microvascular complications mediatingendothelial function impairment. Our assumptionrepresents the first interdisciplinaryapproach in order to clarify thecomplex pathogenesisof microvascularcomplicationsindiabetes.This novel approach aims to acquire the developmentof an individualized approachto diagnosis, prevention and treatment of diabetes related vascular complications.

Conflict of interest

None declared.

References:

1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013.
2. Aiello LP; DCCT/EDIC Research Group Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37(1):17-23.
3. Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am 2013;97:1-18.
4. Winer N and Sowers JR. Epidemiology of diabetes. J. Clin. Pharmacol. 20 04;44:397-405.

5. Tousoulis D, Kampoli AM, Stefandis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives.Curr Vasc Pharmacol 2012; 10:19-32.

6. Tousoulis D, Kampoli AM, Tentolouris C, Papageorigiu N, Stefandis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012; 10:4-18.

7. Capellini VK, Celoto AC, Baldo CF, et al. Diabetes and vascular disease: basis concepts of nitric oxide physiology, endothelial dysfunction, oxidative stress and therapeutic possibilities. Curr Vasc Pharmacol 2010; 8:526-44.

8. Kershaw EE, Flier J S. Adipose tissue as an endocrine organ. The Journal of Clinical Endocrinology & Metabolism 2004; 89(6), 2548-2556.

9. Symons JD, McMillin SL, Riehle C et al. Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ Res 2009; 104: 1085–1094

10. Tousoulis D, Tsarpalis K, Cokkinos D, Stefanadis C. Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications. Diabetes Obes Metab 2008; 10(10):834-42.

11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med 1993; 329: 977–986

12. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 1995; 310, 83–88.

13. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11:1278–1289.

14. Stehouwer CD, Gall M A, Twisk J W, Knudsen E, Emeis JJ and Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157–1165.

15. Jin SM, Noh CI, Yang SW et al. (2008) Endothelial Dysfunction and Microvascular Complications in Type 1 Diabetes Mellitus. J Korean Med Sci 23:77-82.

16. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-432.

17. Uckaya G, Ozata M, Bayraktar Z, Erten V, Bingol N, Ozdemir IC. Is leptin associated with diabetic retinopathy? Diabetes Care 2000; 23: 371–376.

18. Matsuda M, Kawasaki F, Inoue H et al. Possible contribution of adipocytokines on diabetic neuropathy. Diabetes Res Clin Pract 2004; 66: S121–S123

19. Hanai K, Babazono T, Takagi M et al. Obesity as an effect modifier of the association between leptin and diabetic kidney disease. J Diabetes Investig 2014; 23:5(2):213-20.

20. De Block CEM, De Leeuw IH, Van Gaal LF. Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients. Diabetes Care 2005; 28:7 1649-1655.

21. Beltowski J, Wojcicka G, Borkowska E. Human leptin stimulates systemic nitric oxide production in the rat. Obes Res. 2002;10:939–946.

22. Kimura K, Tsuda K, Baba A, Kawabe T, Boh-oka S, Ibata M, Moriwaki C, Hano T, Nishio I. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000;273:745–749.

23. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008; 295(4):H1514-21

24. Yilmaz MI, Sonmez A, Acikel C. Adiponectin may play a part in the pathogenesis of diabetic retinopathy. Eur J Endocrinol 2004; 151(1):135-40.

25. Yenicesu M, Yilmaz MI, Caglar K. Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients. Clin Nephrol 2005 (1):12-9.

26. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ.Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003;278(45):45021–45026.

27. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315(2):264–271.

28. Cao Y, Tao L, Yuan Y et al. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009;46(3):413-9.

29. Prior SL, Tang TS, Gill GV, Bain SC, Stephens JW. Adiponectin, total antioxidant status, and urine albumin excretion in the low-risk "Golden Years" type 1 diabetes mellitus cohort. Metabolism 2011; 60(2):173-9.

30. Schalkwijk CG, Chaturvedi N, SchramMT, FullerJH, Stehouwer CD. Adiponectin is inversely associated with renal function in type 1 diabetic patients. The Journal of Clinical Endocrinology & Metabolism 2006; 91(1): 129-135.

31. Jorsal A, Petersen EH, Tarnow L. Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. J Diabetes Complications 2013; 27(6):604-8

32. SharmaK, RamachandraRaoS, QiuG et al. Adiponectin regulates albuminuria and podocyte function in mice. The Journal of clinical investigation 2008; 118(5):1645-1656.

33. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, MatsuzawaY. levated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002; 25(9): 1665-1666.

34. Schäffler A, Büchler C, Müller-Ladner U, Herfarth H, Ehling A, Paul G, Schölmerich J, Zietz B. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004; 36(10):702-7.

35. Azab N, Abdel-Aziz T, Ahmed A, El-deen IM. Correlation of serum resistin level with insulin resistance and severity of retinopathy in type 2 diabetes mellitus. Journal of Saudi Chemical Society 2012.DOI: 10.1016/j.jscs.2012.07.003

36. Osawa H, Ochi M, Kato K et al. Serum resistin is associated with the severity of microangiopathies in type 2 diabetes. Biochemical and biophysical research communications 2007; 355(2), 342-346.

37. Chen C, Jiang J, Lü JM, Chai H, Wang X, Lin PH, Yao Q. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human

coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299(1):H193-201.

38. Li Y, Wang Y, Li Q, Chen Y, Sun SZ, Zhang WD, Jia Q. Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium 2007; 14(4-5):207-14.

39. Firneisz G, Varga T, Lengyel G et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010; 18;5(8):e12226.

40. Lamers D, Famulla S, Wronkowitz N et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60(7):1917-25.

41. Mega C, Teixeira de Lemos E, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F and Reis F. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp. Diabetes Res 2011;e162092.

42. Liu L, Liu J, Wong WT et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension2012 ;60:833–841.

43. Ishii M, Shibata R, Kondo K et al. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2014; pii: jbc.M114.557835. [Epub ahead of print]

44. Mason PR, Jacob R, Corbalan JJ, Kubant R, Ciszewski A, Malinski T. Effects of dipeptidyl peptidase-4 inhibition on endothelial nitric oxide release, bllod pressure and SICAM-1 levels in hypertensive rats. JACC 2012; 59(13): E1543.

45. Kröller-Schön S, Knorr M et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012;96:140–149.